{"id":"W2792937256","doi":"10.1056/nejmoa1712126","title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4643,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; University Hospital Foundation","funders":"Foundation Medicine; Kite Pharma; Genentech; Astellas Pharma; Eisai; Jounce Therapeutics; Takeda Oncology; Mirati Therapeutics; Acceleron; Clovis Oncology; BioMarin Pharmaceutical; Mylan; Celldex Therapeutics; Taiho Pharmaceutical; Horizon Pharma; Ipsen; Array BioPharma; Bayer HealthCare; Exelixis; Sanofi; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Amgen; INOVIO Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; LEO Pharma; Intuitive Surgical; Pfizer; EUSA Pharma; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ipilimumab; Sunitinib; Nivolumab; Renal cell carcinoma; Medicine; Internal medicine; Oncology; Cancer research; Urology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001579729,0.00051826,0.001656737,0.0003910618,0.0002570138,0.0004512078,0.0005038771,0.0005416627,0.002011376],"category_scores_gemma":[0.001726609,0.0002651102,0.0009090487,0.0002420915,0.0004354539,0.0003718052,0.0003014081,0.001062809,0.0002631161],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007302803,"about_ca_system_score_gemma":0.0008609971,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007712047,"about_ca_topic_score_gemma":0.001732556,"domain_scores_codex":[0.9993159,0.0004076926,0.00006401283,0.00008092527,0.00005985607,0.00007170833],"domain_scores_gemma":[0.9991108,0.0003196992,0.0001253902,0.00002783414,0.00003232126,0.0003840553],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8882797,0.008480316,0.006800486,0.0005090388,0.001085942,0.0001065385,0.000108945,0.003839758,0.007710765,0.0001134781,0.0005753434,0.08238962],"study_design_scores_gemma":[0.3846092,0.5771568,0.02478679,0.0001008094,0.001457254,0.0002818518,0.0000893299,0.005893995,0.003601305,0.0003575978,0.001631111,0.00003395927],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969536,0.001995079,0.0001402682,0.0001567549,0.0001030093,0.0002353719,0.00005301014,0.00001468275,0.0003482535],"genre_scores_gemma":[0.9982815,0.0007743998,0.0002614692,0.0001003905,0.00009494693,0.0001764702,0.00006965153,0.00000232052,0.0002389875],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002011376,"threshold_uncertainty_score":0.008354545,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03398449636464475,"score_gpt":0.2907462659043244,"score_spread":0.2567617695396797,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}